Sit to Stand Muscle Power Is Related to Functional Performance at Baseline and After Supervised Exercise Training in Patients with Lower Extremity Peripheral Artery Disease.
Détails
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_674C5AB6D627
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Sit to Stand Muscle Power Is Related to Functional Performance at Baseline and After Supervised Exercise Training in Patients with Lower Extremity Peripheral Artery Disease.
Périodique
European journal of vascular and endovascular surgery
ISSN
1532-2165 (Electronic)
ISSN-L
1078-5884
Statut éditorial
Publié
Date de publication
04/2023
Peer-reviewed
Oui
Volume
65
Numéro
4
Pages
521-527
Langue
anglais
Notes
Publication types: Observational Study ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Patients with peripheral artery disease (PAD) have decreased muscle power, contributing to functional limitations. The sit to stand (STS) is a validated test to assess muscle power in older individuals; however, it has never been investigated in patients with PAD. The relationship between STS muscle power, and common disease related outcomes was evaluated at baseline and following supervised exercise training (SET) in patients with PAD.
This observational study investigated patients with Fontaine stage II. Before and after SET, maximum treadmill walking distance (MWD), functional performance tests (six minute walk, STS, stair climbing, habitual gait speed), and quality of life (Short Form 36 questionnaire) were assessed. Relative (W/kg) STS muscle power was calculated using a validated equation. Multiple regressions models were used.
Ninety-five patients with PAD were included (63.1 ± 12.1 years, 67% male). Relative STS muscle power before: 2.7 W/kg, 95% confidence interval [CI] 2.5 - 2.9; after: 3.3, 95% CI 3.1 - 3.6, MWD before: 367.0 m, 95% CI 302.4 - 431.5; after: 598.4, 95% CI 515.6 - 681.3, six minute walking distance before: 418.3 metres; 95% CI 399.4 - 437.2; after: 468.8; 95% CI 452.7-484.9, stair climbing performance before: 6.8 seconds 95% CI 6.2 - 7.4); after: 5.3; 95% CI 4.9 - 5.7, habitual gait speed before: 1.10 m/s, 95% CI 1.05 - 1.14; after: 1.18, 95% CI 1.14 - 1.22 increased significantly following SET (p < .001). Similarly, physical before: 31.4, 95% CI 29.4 - 33.3; after: 35.8, 95% CI 33.9 - 37.7 and mental before: 39.5, 95% CI 37.0 - 42.0; after: 43.1, 95% CI 40.9 - 45.4 component summaries of the SF-36 also increased significantly (p < .001). Greater relative STS muscle power at baseline was significantly related to greater baseline treadmill (β < .380; p < .002) and functional (β < .597; p < .001) performance, and quality of life (β < .291; p < .050). Larger increases in relative STS muscle power following SET were associated with greater improvements in functional performance (β < .419; p < .009).
The STS test is a valid clinical tool to monitor overall functional status in patients with symptomatic PAD.
This observational study investigated patients with Fontaine stage II. Before and after SET, maximum treadmill walking distance (MWD), functional performance tests (six minute walk, STS, stair climbing, habitual gait speed), and quality of life (Short Form 36 questionnaire) were assessed. Relative (W/kg) STS muscle power was calculated using a validated equation. Multiple regressions models were used.
Ninety-five patients with PAD were included (63.1 ± 12.1 years, 67% male). Relative STS muscle power before: 2.7 W/kg, 95% confidence interval [CI] 2.5 - 2.9; after: 3.3, 95% CI 3.1 - 3.6, MWD before: 367.0 m, 95% CI 302.4 - 431.5; after: 598.4, 95% CI 515.6 - 681.3, six minute walking distance before: 418.3 metres; 95% CI 399.4 - 437.2; after: 468.8; 95% CI 452.7-484.9, stair climbing performance before: 6.8 seconds 95% CI 6.2 - 7.4); after: 5.3; 95% CI 4.9 - 5.7, habitual gait speed before: 1.10 m/s, 95% CI 1.05 - 1.14; after: 1.18, 95% CI 1.14 - 1.22 increased significantly following SET (p < .001). Similarly, physical before: 31.4, 95% CI 29.4 - 33.3; after: 35.8, 95% CI 33.9 - 37.7 and mental before: 39.5, 95% CI 37.0 - 42.0; after: 43.1, 95% CI 40.9 - 45.4 component summaries of the SF-36 also increased significantly (p < .001). Greater relative STS muscle power at baseline was significantly related to greater baseline treadmill (β < .380; p < .002) and functional (β < .597; p < .001) performance, and quality of life (β < .291; p < .050). Larger increases in relative STS muscle power following SET were associated with greater improvements in functional performance (β < .419; p < .009).
The STS test is a valid clinical tool to monitor overall functional status in patients with symptomatic PAD.
Mots-clé
Humans, Male, Aged, Female, Intermittent Claudication, Quality of Life, Peripheral Arterial Disease/diagnosis, Peripheral Arterial Disease/therapy, Exercise, Walking/physiology, Lower Extremity, Muscles, Physical Functional Performance, Exercise Therapy, Physical activity, Quality of life, Rehabilitation, Walking performance
Pubmed
Web of science
Open Access
Oui
Création de la notice
10/01/2023 14:19
Dernière modification de la notice
17/11/2023 8:13
Données d'usage
